12:28 Uhr
ROUNDUP: May präsentiert am Nachmittag Plan B für Brexit-​Deal

Leading Regional Hospital Network in Asia to Offer Champions TumorGraft™ to Cancer Patients

Mittwoch, 26.02.2014 14:25 von PR Newswire

PR Newswire

HACKENSACK, N.J., Feb. 26, 2014 /PRNewswire/ -- Champions Oncology (OTC: CSBR), a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced that a leading hospital network in Asia, Parkway Cancer Centre (PCC), will begin offering Champions TumorGrafts™ to cancer patients at its three facilities in Singapore and network locations throughout South East Asia.  

"Partnering with Parkway Cancer Centre expands our reach in Singapore and enables us to bring TumorGrafts to patients throughout South East Asia," said Ronnie Morris, M.D., President of Champions Oncology. "We have been very impressed with PCCs clinical and business acumen.  They orchestrated a very successful launch with an exciting amount of media and patient exposure."

Dr. Ang Peng Tiam, Medical Director and Senior Consultant of Medical Oncology at Parkway Cancer Centre, added, "The battle against cancer is not an easy one. The silver lining of this reality is that constant advancements in medicines and medical technology are slowly but surely tipping the battle against cancer in our favor. Helping patients achieve the best possible outcome is what PCC strives to achieve, as well as keeping tabs on better drugs and advances in medical technology. The preliminary results demonstrated by the use of Champions TumorGraft in identifying the agents that are most likely to help each individual cancer patient are encouraging. This new approach offers hope to patients by providing a better chance of fighting the disease."

Champions TumorGraft is a personalized approach to guide treatment decisions for cancer patients.  A piece of the patient's living tumor is removed during surgery or biopsy and implanted in immune-deficient mice. After the TumorGraft grows, still closely resembling the patient's tumor, Champions Oncology tests drug treatments in the TumorGraft and measures the response. Champions Oncology early experience has demonstrated that the TumorGraft has high rates of predictability using multiple therapies, including single-agent and combination chemotherapy regimens, targeted biological drugs and anti-angiogenics.

A TumorGraft, once grown, can be preserved as a living sample for future patient use. These banked TumorGrafts can be re-grown and tested in the event of cancer progression or recurrence. They have been successfully engrafted in most solid tumor types, including colorectal, ovarian, lung, breast, sarcoma, pancreatic, stomach, esophageal and others.

About Parkway Cancer Centre

Parkway Cancer Centre offers comprehensive cancer treatment with a highly skilled, multi-disciplinary team comprising of consultant medical specialists, nurses, counsellors and other para-medical professionals to meet the specific needs of cancer patients. The Centre uses the latest technologies in cancer treatment to help patients access proven innovative therapies for the best clinical outcomes. Committed to providing a comprehensive holistic treatment of cancers in a safe and comfortable environment, the Centre ensures that patients are well-attended to by caring and experienced professionals.

About Champions Oncology

Champions Oncology, Inc. is engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs. The company's TumorGraft technology platform is a novel approach to personalizing cancer care based upon the implantation of primary human tumors in immune deficient mice followed by propagation of the resulting engraftments, or TumorGrafts, in a manner that preserves the biological characteristics of the original human tumor in order to determine the efficacy of a treatment regimen. The company uses this technology in conjunction with related services to offer solutions for two customer groups: Personalized Oncology Solutions, in which results help guide the development of personalized treatment plans, and Translational Oncology Solutions, in which pharmaceutical and biotechnology companies seeking personalized approaches to drug development can lower the cost and increase the speed of developing new drugs. TumorGrafts are procured through agreements with a number of institutions in the United States and overseas as well as through the company's Personalized Oncology Solutions business. For more information, please visit

SOURCE Champions Oncology, Inc.